Document is current

Article History

Received: 24 January 2022

Accepted: 30 August 2022

First Online: 12 November 2022

Competing interests

: D.A., K.R.C., and H.Z. declare they do not have any non-financial competing interest but the financial competing interests are: D.A. has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Sanofi, Evonik, Roche Diagnostics and GE Health, and served as paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly, Cognetivity, Enterin, Acadia, Sygnature and Biogen; K.R.C. is in the advisory board of AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Therevance, Scion, Britannia, Acadia, 4D, has received honoraria for lectures from AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial and reports grants for investigator initiated studies from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial, academic grants from EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, PDNMG, Kirby Laing Foundation, NPF, MRC, Wellcome Trust; H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Programme (outside submitted work). A.R., P.Z., C.F., L.L.G., D.T., A.H., A.H., S.R., And L.B report no competing interests.